Bio-Techne Corporation (TECH)
Bio-Techne Corporation (TECH) is a healthcare company (biotechnology) based in the United States. The share price is $72.79, down 0.01% on the day, which values the company at $11.43B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $72.79−0.01% today
- Market value
- $11.43B
- P/E ratio
- 66.8×last 12 months
- Forward P/E
- 31.5×
- Dividend yield
- 0.33%
- Funk Score
- 56/100
- Against its own history
- Above its usual priceusual price $63.41
- 200-week average
- $67.698% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Bio-Techne Corporation in more detail
TECH trades at 66.8× its last twelve months' earnings, 31.5× next year's expected earnings, 9.3× sales. Measured against its own history, the price is 15% above what its usual multiples would imply ($63.41) — above its usual price. It sits 8% above its 200-week average of $67.69.
Over the last five fiscal years Bio-Techne Corporation has compounded revenue 5.5% a year, earnings per share 5.9% a year, free cash flow -3.1% a year. Its Funk Score is 56 out of 100 (financial strength 9.2, profitability 6.4, growth 3.5, value 3.2, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
7 of the superinvestors tracked here hold TECH, including Sequoia Fund team (3.9% of the portfolio), Wallace Weitz (1.3% of the portfolio), Lee Ainslie (1.0% of the portfolio).
Superinvestors holding TECH
7 of the investors tracked here report a position in their latest 13F filing.
- Sequoia Fund team Ruane, Cunniff & Goldfarb3.94% of portfolio · $242.3M · trimmed · Q3 2026
- Wallace Weitz Weitz Investment Management1.25% of portfolio · $18.3M · trimmed · Q3 2026
- Lee Ainslie Maverick Capital0.98% of portfolio · $108.5M · trimmed · Q2 2026
- Mairs & Power team Mairs & Power0.85% of portfolio · $92.3M · trimmed · Q3 2026
- Henry Ellenbogen Durable Capital Partners0.35% of portfolio · $35.5M · trimmed · Q2 2026
- Paul Tudor Jones Tudor Investment Corp0.28% of portfolio · $66.6M · new · Q2 2026
- Larry Robbins Glenview Capital Management0.08% of portfolio · $4.1M · trimmed · Q2 2026
Health Care companies of similar size
- Fresenius Medical CareFMS
- Kymera TherapeuticsKYMR
- DaVitaDVA
- Halozyme TherapeuticsHALO
- Universal Health ServicesUHS
- RepligenRGEN
- BioMarin PharmaceuticalBMRN
- AvantorAVTR
- Ensign GroupENSG
- VaxcytePCVX
- Bio-Rad LaboratoriesBIO
- Molina HealthcareMOH
Side by side:TECH vs RGEN (Bio-Techne Corporation vs Repligen)TECH vs UHS (Bio-Techne Corporation vs Universal Health Services)TECH vs HALO (Bio-Techne Corporation vs Halozyme Therapeutics)TECH vs DVA (Bio-Techne Corporation vs DaVita)TECH vs BMRN (Bio-Techne Corporation vs BioMarin Pharmaceutical)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Bio-Techne Corporation (TECH): questions and answers
What is TECH's P/E ratio?
Bio-Techne Corporation trades at 66.8× its last twelve months' earnings and 31.5× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 19.5× to 129.4×, with a median of 45.0×.
What is TECH's PEG ratio?
Bio-Techne Corporation's PEG ratio is 2.18 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Bio-Techne Corporation's market cap?
Bio-Techne Corporation is valued at $11.43B at a share price of $72.79.
Is TECH overvalued or undervalued?
Against its own history, TECH is above its usual price: the price is 15% above the $63.41 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is TECH above its 200-week moving average?
Yes. TECH is 7.5% above its 200-week average of $67.69. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Bio-Techne Corporation growing?
Over the last five fiscal years Bio-Techne Corporation's revenue grew 5.5% a year and its earnings per share 5.9% a year; over ten years revenue grew 9.3% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Bio-Techne Corporation (TECH) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TECH
Underlying data: Yahoo Finance; company filings with the SEC.